- Open Access
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
© Deshaies; licensee BioMed Central Ltd. 2014
- Published: 11 November 2014
Genomic alterations may make cancer cells more dependent than normal cells on mechanisms of proteostasis, including protein folding and degradation. This proposition is the basis for the clinical use of proteasome inhibitors to treat multiple myeloma and mantle cell lymphoma. However, proteasome inhibitors have not proved effective in treating other cancers, and this has called into question the general applicability of this approach. Here, I consider possible explanations for this apparently limited applicability, and discuss whether inhibiting other broadly acting components of the ubiquitin-proteasome system - including ubiquitin-activating enzyme and the AAA-ATPase p97/VCP - might be more generally effective in cancer therapy.
- Multiple Myeloma
- Unfold Protein Response
- Mantle Cell Lymphoma
The ubiquitin-proteasome system (UPS) is the major mechanism by which proteins are degraded in the cytoplasm and nucleus of eukaryotic cells and as such is a key player in maintaining protein homeostasis . Proteins destined to be degraded by the UPS are tagged for destruction by conjugation to the small protein ubiquitin through the action of ubiquitin-conjugating (E2) and ubiquitin ligase (E3) enzymes, which can result in the assembly of ubiquitin chains on one or more lysine residues within the substrate. Proteins modified with an ubiquitin chain bind to ubiquitin receptors that link them to the 26S proteasome. The 26S proteasome is a large proteolytic complex that degrades ubiquitin-modified proteins and recycles the ubiquitin for future use.
The proteasome inhibitor bortezomib provided the first direct evidence that it is possible to inhibit the UPS in a manner that is lethal to at least some cancer cells while mostly sparing normal cells . Before discussing bortezomib in detail, a primer on the structure and mechanism of the 26S proteasome is in order.
It is thought that substrates are bound to the 26S proteasome in a manner that enables them to be grasped by the Rpt1-6 proteins, which are AAA ATPases that use the energy derived from ATP hydrolysis to unfold substrates, open the normally closed gate at the end of the 20S cylinder to admit substrate, and translocate the substrate through a pore in the center of the Rpt ring and into the internal chamber of the 20S cylinder. As substrate is being translocated through the Rpt ring, the Rpn11 subunit of the 19S RP, which is positioned immediately above the channel through the Rpt ring, scans for ubiquitin chains. Rpn11 is a protease that removes ubiquitin chains as the substrate translocates by, which is thought to prevent the chains from clogging up the entry channel into the proteasome.
Inhibition of 20S peptidase activity with bortezomib is highly cytotoxic to the plasma cell cancer multiple myeloma (MM) , and bortezomib has been an effective therapy for treating patients with this disease as well as mantle cell lymphoma (MCL) -. However, despite its considerable success as a therapy for MM and MCL, bortezomib has not been approved for treating other cancers. This is not for lack of effort: over 700 bortezomib trials have or are being run , including many in indications other than MM and MCL, in attempts to identify cancers that might respond favorably. This clinical experience is consistent with in vitro data: although brief exposure to proteasome inhibitors is highly cytotoxic to MM cells, it is not more cytotoxic to solid tumor cell lines than it is to non-transformed cells . These data raise an obvious question - why aren’t proteasome inhibitors more broadly effective as cancer therapeutics - and pose a serious challenge to the generality of the proteotoxic crisis hypothesis.
Most attempts to explain why proteasome inhibitors work in MM and MCL but not in other cancers have focused on physiology. MM cells often have an elevated level of activity of the pro-survival transcription factor NF-κB . Indeed, genomic and transcriptomic analyses have revealed recurrent alterations in MM cells that deregulate NF-κB -. Proteasome inhibitors block degradation of the NF-κB inhibitor IκB by the proteasome, thereby inhibiting inducible NF-κB activity . This could explain why MM cells, particularly those accustomed to a high level of constitutive NF-κB activity, might be sensitive to bortezomib. However, this is unlikely to be the key mechanism of action, because an inhibitor of the IκB kinase IKK (which is also required for IκB degradation) is not as effective as bortezomib at killing MM cells . Moreover, bortezomib does not downregulate NF-κB activity in primary MCL and MM cells or in MM xenografts ,.
An additional explanation for the sensitivity of MM cells to bortezomib is that they exhibit a lower threshold for induction of a lethal `unfolded protein response’ (UPR) . The UPR is a homeostatic response that is mobilized by the presence of unfolded proteins in the lumen of the endoplasmic reticulum (ER) . Under normal conditions, these unfolded proteins are retrotranslocated back to the cytosol, where they are degraded by the proteasome in a process known as ER-associated degradation (ERAD) . However, when the burden of unfolded proteins in the ER lumen is high, activation of the UPR enables cells to cope with this problem by inhibiting protein synthesis to reduce the load on the ER while upregulating genes to enhance the biogenic capacity of the ER . However, sustained UPR signaling can eventually commit a cell to apoptosis. Inhibition of the proteasome can activate an apoptotic UPR in myeloma cells , presumably by interfering with ERAD. MM plasma cells may be particularly prone to a cytotoxic UPR because of their physiological role in producing large quantities of antibody ,. This perches the cells on the edge of proteotoxic crisis, and transient inhibition of the proteasome is the nudge that pushes them into the abyss. Exposure to proteasome inhibitors for as little as one hour can suffice to consign MM plasma cells to an apoptotic fate, whereas much higher levels of drug or longer exposures are normally required to induce cell death in solid tumor cells  and possibly in MM stem cells that are at an earlier developmental stage . Notably, cancer cells isolated from MCL patients dosed with bortezomib do not exhibit a strong UPR but instead show evidence of NRF2 activation, suggesting that MM and MCL may respond to bortezomib therapy for different reasons . A deeper understanding of why some MCL patients respond to bortezomib could suggest other cancers that may be prone to respond to proteasome inhibition in mono- or combination therapy.
If the proteotoxic crisis hypothesis is correct, it should be possible to identify cancer types and treatment regimes for which there is a favorable therapeutic index for killing tumor cells with mutation-riddled genomes while sparing normal cells. One place to start looking is in cancers that originate in secretory tissues, including neuroendocrine tumors in general and insulinoma in particular. However, the search need not be limited to `response’ tumors. Indeed, it was recently argued that the sensitivity of MM cells to proteasome inhibitors can be generalized to a simple metric comprising the rate of degradation of newly synthesized proteins (which is a crude measure of PQC) divided by the level of proteasome activity ,. Using this metric, which is more broadly focused on PQC and does not necessarily invoke a unique role for ERAD or UPR, it may be possible to identify other cancers that are likely to be responsive to proteasome inhibition.
When injected at its standard clinical dose (1.3 mg/m2), bortezomib elicits approximately 65% inhibition of β5 activity in whole blood lysate at the point of the sawtooth . Importantly, biochemical studies suggest that inhibition of β5 is likely to be insufficient, and co-inhibition of the β1 site, which is 10-fold less sensitive to bortezomib than β5, is required to prevent protein breakdown . Furthermore, whole blood β5 activity is more sensitive to bortezomib than solid tissues. At its maximum tolerated dose in mice, bortezomib inhibits β5 activity to approximately 90% in whole blood, but only approximately 75% in the adrenal gland and 50% in a myeloma cell xenograft . A very recent study reported that following a 1 hour pulse treatment with 100 nM bortezomib (which exceeds by two-fold the concentration achieved following a subcutaneous dose), β5 activity was eliminated but proteasome-dependent proteolysis was inhibited by only 23 to 55% across seven MM cell lines and >70% cell death was observed in only one of the lines . This study suggests that the degree of proteasome (as opposed to β5) inhibition elicited by bortezomib in tumor tissue in vivo - which has not been reported - is likely to be quite modest. Perhaps the depth and duration of proteasome suppression achieved in vivo is sufficient to kill MM plasma cells teetering on the edge of UPR-dependent apoptosis (Figure 3B), but not strong and long enough to kill MM stem cells and most solid tumor cells, including those that may have a heightened dependency on the UPS.
If this idea is correct, it suggests that it might be possible to expand the range of cancers in which proteasome inhibitor therapy is effective by increasing the extent of inhibition and reducing the rate at which proteasome activity recovers following inhibition. This idea was part of the motivation underlying the partnership that Craig Crews and I formed to co-found Proteolix. The Crews lab had discovered that the natural product epoxomicin is a covalent, irreversible inhibitor of the same β5 active site of the proteasome that is inhibited by bortezomib . They then went on to develop YU101, which is a modified form of epoxomicin that is more specific for the β5 site than the parent molecule . We reasoned that greater specificity might allow for a better tolerability profile than bortezomib and hence the potential to achieve stronger inhibition, whereas irreversibility would result in a longer duration of proteasome inhibition because the only way to recover activity would be to synthesize new proteasome. Proteolix modified YU101 to generate carfilzomib , which has emerged as a successful second-generation proteasome inhibitor drug. Carfilzomib, like bortezomib, is an injectable drug that is cleared rapidly from plasma . Nevertheless, it has shown efficacy in relapsed and refractory MM patients  and has shown very promising activity in earlier stage myeloma patients in combination with lenalidomide plus dexamethasone . By contrast, limited activity was observed in a phase I/II study that included four different solid tumor types . However, as of October 2014 there are 63 open clinical trials involving carfilzomib listed on clinicaltrials.gov , including in kidney, prostate, lung, and ovarian cancer, and so the jury is still out. Interestingly, despite carfilzomib’s irreversibility, the rate of recovery of proteasome β5 activity in tissues other than whole blood following carfilzomib administration in mice is not very much slower than that observed with bortezomib . Thus, synthesis of new proteasomes appears to be a powerful homeostatic mechanism that minimizes the duration of proteasome inhibition following a pulse of bortezomib or carfilzomib.
Alternative paths to testing the hypothesis that cancer cells are vulnerable because of their heightened dependency on protein quality control
A second approach, which is also already underway, is to develop oral proteasome inhibitors that would allow for more flexibility in dosing. Ixazomib and oprozomib are oral analogs of bortezomib and carfilzomib, respectively, that are in mid- to late stage clinical development as therapies for MM. As noted above, current therapy with bortezomib and carfilzomib results in a sawtooth pattern of β5 inhibition (Figure 3A). Is it possible that maintaining a more constant level of inhibition for a longer duration via repetitive oral dosing (Figure 4C) might enable killing of solid tumor cells while sparing normal cells? It is difficult to test this hypothesis with injectable agents like bortezomib and carfilzomib because administration of the drug requires a visit to a doctor, but this approach could be accessible with oral agents, provided that they are tolerated by the gastrointestinal tract.
A third approach, related to the one described above, is to develop oral agents that target other aspects of proteasome function (Figure 4D). The proteasome is an extremely complex enzyme comprising multiple subcomplexes each of which has enzymatic sites that are essential for proteasome activity. There is a great deal of precedent indicating that agents that hit the same target but do so with a different molecular scaffold or by a different mechanism often have substantially different clinical properties. One example (among many) is the difference between vinca alkaloid antimicrotubule agents . Two novel small molecules - b-AP15 and RA190 - that are proposed to kill cancer cells by inhibiting the proteasome have been reported. B-AP15 simultaneously inhibits the proteasome-associated deubiquitinating enzymes UchL5 and Usp14, whereas RA190 binds and inhibits the ubiquitin receptor subunit Rpn13 ,. In addition, other targets, including Rpn11, the Rpt AAA ATPases, and the pockets in the 20S to which the Rpt subunits dock, should be drugable with small molecules. Although a high-throughput screening (HTS) assay that monitors assembly of 19S RPs with 20S cylinders has not been reported, an HTS assay for identifying inhibitors of Rpn11 and the Rpt enzymes was originally developed at Proteolix  and refined in my laboratory . Implementation of our method allowed us to identify small molecules that are candidate Rpn11 inhibitors. It remains to be seen whether suitable molecules that inhibit the Rpt ATPases can be identified by this approach. A great deal of work needs to be done to develop clinical-grade molecules that inhibit other aspects of proteasome function, but the success of bortezomib and carfilzomib provides motivation for pursuing these targets.
The fourth approach is to combine proteasome inhibitors with other agents that influence PQC. This includes inhibitors of Hsp90 and HDAC6, as well as agents discussed in the next paragraph. To date, several efforts registered at clinicaltrials.gov have been initiated and/or completed. Whereas the data for Hsp90 plus proteasome inhibitor combinations have yet to yield an obvious clinical benefit, the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone yielded a statistically significant increase in progression-free survival compared to the control arm lacking panobinostat . Ironically, the most successful combination with proteasome inhibitors has been the immunomodulatory agent lenalidomide, even though, superficially, it would appear that proteasome inhibitors and lenalidomide should counteract each other, because lenalidomide appears to work by activating degradation of the IKZF1 and IKZ3 transcription factors -.
A fifth approach to addressing the proteotoxic crisis hypothesis is to identify other suitable targets in the UPS besides the 26S proteasome. Multiple efforts have been initiated in this direction. There have been many programs to generate inhibitors of E3 ubiquitin ligases and deubiquitinating enzymes, but these are not covered here because in all of these cases, the intention has been to prevent the degradation of tumor suppressor proteins (for example, p27 or p53) or accelerate the degradation of proto-oncoproteins (for example, Hdm2), and hence these efforts do not fit in the `proteotoxic crisis’ category elaborated on here.
In addition, there have been attempts to target more broadly acting components of the UPS, including the Nedd8 activating enzyme (NAE) . Nedd8 is an ubiquitin-like protein that is conjugated to cullins following its activation by NAE. NAE-dependent conjugation of Nedd8 switches on the activity of cullin-RING ubiquitin ligases (CRLs), which number in the hundreds and play important roles in cell cycle control, signaling, and DNA damage, but have not been extensively linked to PQC. Thus, an NAE inhibitor is also not predicted to kill cancer cells by inducing proteotoxic crisis. The closely related ubiquitin-activating enzyme (UAE), on the other hand, is required for all ubiquitin-dependent degradation by the proteasome as well as non-degradative signaling by monoubiquitination, and thus its inhibition is likely to have very broad effects, including blockade of PQC and induction of proteotoxicity. Two different inhibitors of UAE have been reported - PYR41  and the adenine sulfamate analog Compound I . PYR-41 blocks accumulation of ubiquitin conjugates, promotes accumulation of p53, and preferentially kills transformed cells that express p53. However, the specificity of this molecule for UAE versus other cysteine-based enzymes was not evaluated in depth. Meanwhile, Millennium Pharmaceuticals’ Compound I blocks formation of E2-ubiquitin thioesters and polyubiquitin conjugates in cells, but its effects on cell viability were not reported. However, clinicaltrials.gov lists an active phase 1 trial sponsored by Millennium for the ubiquitin-activating enzyme inhibitor MLN7243 . Because there are no publications yet that name this molecule, it is not known how it relates to Compound I.
Other targets that have been pursued in the broader arena of PQC include the transmembrane signaling enzymes IRE1 - and PERK -. Neither of these proteins is a UPS component per se, but I discuss them here briefly because they are involved in a regulatory response that is intimately connected to the UPS. Both PERK and IRE1 are transmembrane proteins of the ER membrane that contain cytosolic protein kinase domains. IRE1 also contains a cytosolic endoribonuclease activity. Both of these proteins sense misfolded proteins in the ER and employ their kinase (PERK) or nuclease (IRE1) domains to signal the presence of unfolded proteins in the ER to the cytosol and nucleus. This results in induction of the UPR, leading to downregulation of general translation and upregulation of proteins that increase the biosynthetic capacity of the ER. Inhibition of PERK or IRE1 thus has potential to induce a proteotoxic crisis by preventing the UPR in cancers such as MM that may rely on the UPR for survival. Indeed, both PERK  and IRE1  inhibitors are cytotoxic to cancer cells and have shown activity in multiple myeloma xenograft models. However, the PERK inhibitor exhibited pancreatic toxicity, which may complicate its clinical development. There has yet to be a human clinical trial that targets either enzyme.
Several years ago, my laboratory embarked on the path of identifying a new target in PQC. The criteria we set forth was that the ideal target should be: (i) drugable (that is, an enzyme); (ii) a key player in PQC; and (iii) mutated, amplified, hyperactivated, or overexpressed in some cancers, consistent with the idea that its activity contributes to the cancer lifestyle. To this, we added the optional criterion that an optimal target would be required for both NF-κB activation and ERAD. In surveying the UPS landscape we settled on the AAA ATPase p97, also known as valosin-containing protein (VCP). At that time, p97 was well-known to be required for ERAD  and had been linked to NF-κB regulation by co-immunoprecipitation studies . Recent functional studies have confirmed the significance of the physical interactions . p97 was also known to be overexpressed in multiple cancers -, pointing to a possible addiction .
Despite the relative paucity of insight into the mechanism of p97 function, considerable progress has been made recently in linking p97 to various substrates and quality control processes within the UPS. In addition to ERAD (Figure 5 upper left), it has been shown that p97 participates in multiple PQC pathways, including ribosome-associated degradation (RAD; Figure 5 upper right) of peptides produced from defective mRNAs - and clearance of ribonucleoprotein stress granules . The connection between p97 and autophagy - may be of particular significance, because cells can adapt to genetic suppression of proteasome function by upregulating autophagy  - an option that might not be available in a cell exposed to a p97 inhibitor. Taken together, these data implicate p97 as a critical player central to protein homeostasis. In addition, p97 has been linked to numerous other degradation pathways in the UPS. For a more thorough discussion of the PQC and non-PQC functions of p97, please consult ,.
To screen for p97 inhibitors, we developed an assay to monitor the action of p97 in cells by exploiting the observation that proteins fused to the carboxyl terminus of ubiquitin are degraded by the `ubiquitin fusion degradation’ (UFD) pathway, of which p97 is a component . Our assay relies on accumulation of UbG76V-GFP using the rapidly reversible proteasome inhibitor MG132 . MG132 is then removed and the decay of the pre-accumulated UbG76V-GFP signal is monitored in the presence of the protein synthesis inhibitor cycloheximide. To evaluate specificity, we monitor degradation of an ODD-luciferase chimera (ODD is the oxygen-dependent degradation domain from HIF-1α) . p97 is not required for ODD-luciferase degradation, and hence p97 inhibitors stabilize UbG76V-GFP but not ODD-luciferase . By this criterion, DBeQ was identified as a selective p97 inhibitor and is the first selective inhibitor of an AAA ATPase activity. Structure-activity relationships analysis of DBeQ identified the more potent derviatives ML240 and ML241 (Figure 6G,H) . Whereas all three compounds stabilize UbG76V-GFP, cause accumulation of ubiquitin conjugates, and inhibit degradation of an ERAD substrate, DBeQ and ML240 also cause accumulation of LC3-II (indicative of a block to autophagy) and induce rapid cell death (with modest selectivity for transformed cells), whereas ML241 does not. The basis for this different behavior remains unclear.
NMS859 and NMS873 (Figure 6I,J), arose from a high-throughput screen for p97 ATPase inhibitors followed by a structure-activity relationships analysis ,. Of particular interest is NMS873, which is a reversible, allosteric inhibitor of p97 ATPase. It is the most potent p97 ATPase inhibitor reported to date, with an IC50 of approximately 30 nM. Similar to DBeQ, NMS873 impinges on both the UPS and autophagy, and is cytotoxic across a broad range of cancer cell lines. Interestingly, unlike proteasome inhibitors, it is not more cytotoxic to MM cells than to other cancer cells. Its relative cytotoxicity in non-transformed cells was not reported.
To explore further the clinical potential of ML240 and ML241, as well as a small-molecule scaffold that inhibits both Rpn11 and the Csn5 subunit of the COP9-signalosome complex (not discussed here), my partners and I launched Cleave Biosciences. Cleave has made rapid progress on the ML240 scaffold, and the derivative CB-5083 recently entered human phase I trials in MM and solid tumors .
It remains to be seen whether cancer cells in their natural environment are more sensitive than normal cells to the proteotoxicity induced by UAE and p97 inhibitors, and whether aggravation of proteotoxic stress in cancer can be achieved with an acceptable side effect profile. With UAE and p97 inhibitors now in the clinic, we should not have to wait much longer for an answer.
The proteotoxic crisis hypothesis suggests the attractive prospect that it may be possible to attack a broad range of human cancers by taking advantage of their presumed heightened dependence on PQC pathways. This heightened dependency is predicted to arise from the very mutations and genomic instabilities that fuel development of the cancer in the first place. The clinical experience to date with the proteasome inhibitor bortezomib on the one hand suggests that the proteotoxic crisis hypothesis may apply to at least some cancers, but on the other hand may not be broadly applicable. However, the limited efficacy of bortezomib in solid tumors may be due to the pharmacology of the existing proteasome inhibitors and the existence of a cellular homeostatic mechanism that enables a compensatory response to proteasome inhibition, rather than a problem with the proteotoxic crisis hypothesis per se. New approaches to inhibiting the proteasome or other UPS targets like UAE and p97 may provide a more salient test of the hypothesis that cancer cells, broadly speaking, are more dependent on PQC pathways than normal cells and thus should be selectively vulnerable to inhibition of PQC.
I thank Chris Kirk, Rusty Lipford, Mark Rolfe, and Rati Verma for comments on the manuscript. I am an Investigator of the Howard Hughes Medical Institute and work in my lab on the topics covered here was supported in part by HHMI and NIH (R01CA164803, R03MH085687, R21NS071523, and R03DA032474).
- Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem. 1998, 67: 425-479.PubMedGoogle Scholar
- Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science. 2008, 319: 916-919.PubMedGoogle Scholar
- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW: Cancer genome landscapes. Science. 2013, 339: 1546-1558.PubMed CentralPubMedGoogle Scholar
- Weaver BA, Cleveland DW: Does aneuploidy cause cancer?. Curr Opin Cell Biol. 2006, 18: 658-667.PubMedGoogle Scholar
- Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE, Amon A: Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science. 2008, 322: 703-709.PubMed CentralPubMedGoogle Scholar
- Torres EM, Dephoure N, Panneerselvam A, Tucker CM, Whittaker CA, Gygi SP, Dunham MJ, Amon A: Identification of aneuploidy-tolerating mutations. Cell. 2010, 143: 71-83.PubMed CentralPubMedGoogle Scholar
- Warner JR, Mitra G, Schwindinger WF, Studeny M, Fried HM: Saccharomyces cerevisiae coordinates accumulation of yeast ribosomal proteins by modulating mRNA splicing, translational initiation, and protein turnover. Mol Cell Biol. 1985, 5: 1512-1521.PubMed CentralPubMedGoogle Scholar
- Dephoure N, Hwang S, O'Sullivan C, Dodgson SE, Gygi SP, Amon A, Torres EM: Quantitative proteomic analysis reveals posttranslational responses to aneuploidy in yeast. eLife. 2014, 3: e03023-PubMed CentralPubMedGoogle Scholar
- Williams BR, Amon A: Aneuploidy: cancer's fatal flaw?. Cancer Res. 2009, 69: 5289-5291.PubMed CentralPubMedGoogle Scholar
- Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009, 136: 823-837.PubMed CentralPubMedGoogle Scholar
- Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005, 5: 761-772.PubMedGoogle Scholar
- Guo JY, Xia B, White E: Autophagy-mediated tumor promotion. Cell. 2013, 155: 1216-1219.PubMed CentralPubMedGoogle Scholar
- Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, Amon A: Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science. 2007, 317: 916-924.PubMedGoogle Scholar
- Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004, 4: 349-360.PubMedGoogle Scholar
- Finley D: Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 2009, 78: 477-513.PubMed CentralPubMedGoogle Scholar
- Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005, 2: 357-362.PubMedGoogle Scholar
- Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM: Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005, 65: 7896-7901.PubMedGoogle Scholar
- Kisselev AF, Callard A, Goldberg AL: Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006, 281: 8582-8590.PubMedGoogle Scholar
- Matyskiela ME, Lander GC, Martin A: Conformational switching of the 26S proteasome enables substrate degradation. Nat Struct Mol Biol. 2013, 20: 781-788.PubMed CentralPubMedGoogle Scholar
- Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005, 102: 8567-8572.PubMed CentralPubMedGoogle Scholar
- Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005, 23: 667-675.PubMedGoogle Scholar
- O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005, 23: 676-684.PubMedGoogle Scholar
- Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005, 352: 2487-2498.PubMedGoogle Scholar
- ClinicalTrials.gov, search term "bortezomib". In , [http://clinicaltrials.gov/ct2/results?term=bortezomib&Search=Search]
- Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67: 6383-6391.PubMedGoogle Scholar
- Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 2001, 115: 279-286.PubMedGoogle Scholar
- Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007, 12: 115-130.PubMed CentralPubMedGoogle Scholar
- Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007, 12: 131-144.PubMed CentralPubMedGoogle Scholar
- Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Getz G, Rosenberg M, Golub TR: Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014, 25: 91-101.PubMed CentralPubMedGoogle Scholar
- Palombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994, 78: 773-785.PubMedGoogle Scholar
- Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002, 277: 16639-16647.PubMedGoogle Scholar
- Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009, 114: 1046-1052.PubMed CentralPubMedGoogle Scholar
- Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008, 7: 40-PubMed CentralPubMedGoogle Scholar
- Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006, 107: 4907-4916.PubMed CentralPubMedGoogle Scholar
- Walter P, Ron D: The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011, 334: 1081-1086.PubMedGoogle Scholar
- Smith MH, Ploegh HL, Weissman JS: Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science. 2011, 334: 1086-1090.PubMedGoogle Scholar
- Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67: 1783-1792.PubMedGoogle Scholar
- Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE: Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013, 24: 289-304.PubMed CentralPubMedGoogle Scholar
- Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A: Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011, 17: 5101-5112.PubMed CentralPubMedGoogle Scholar
- Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P: Pivotal Advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukocyte Biol. 2012, 92: 921-931.PubMedGoogle Scholar
- Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF: Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One. 2013, 8: e56132-PubMed CentralPubMedGoogle Scholar
- Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22: 2108-2121.PubMedGoogle Scholar
- Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J: Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010, 70: 1970-1980.PubMedGoogle Scholar
- Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002, 99: 14374-14379.PubMed CentralPubMedGoogle Scholar
- Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Kruger E: Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem. 2003, 278: 21517-21525.PubMedGoogle Scholar
- Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ: Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One. 2011, 6: e27996-PubMed CentralPubMedGoogle Scholar
- Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002, 8: 2505-2511.PubMedGoogle Scholar
- Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999, 96: 10403-10408.PubMed CentralPubMedGoogle Scholar
- Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM: Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell. 2001, 7: 411-420.PubMedGoogle Scholar
- O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009, 15: 7085-7091.PubMed CentralPubMedGoogle Scholar
- Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012, 120: 2817-2825.PubMed CentralPubMedGoogle Scholar
- Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R: Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013, 122: 3122-3128.PubMed CentralPubMedGoogle Scholar
- Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE, Wang Z, Lee S, Jones SF, Infante JR: A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013, 72: 861-868.PubMed CentralPubMedGoogle Scholar
- ClinicalTrials.gov, search term, "carfilzomib". In , [http://clinicaltrials.gov/ct2/results?term=carfilzomib&recr=Open]
- Rowinsky E: The Vinca Alkaloids. Holland-Frei Cancer Medicine. Edited by: Kuffe DW, Pollock RE, Weischselbaum RR. 2003, BC Decker, Hamilton (ON)Google Scholar
- Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB: A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013, 24: 791-805.PubMedGoogle Scholar
- Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC: A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014, 123: 706-716.PubMed CentralPubMedGoogle Scholar
- Parlati F, Aujay M, Bennett MK: Substrate for Rpn11 enzymatic activity. In United States: Proteolix; 2010.Google Scholar
- PubChem: Summary assay for small molecule inhibitors of Rpn11 in a Fluorescent Polarization assay. In , [http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=588509&loc=ea_ras]
- Richardson PG, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa B-R, Corrado C, San-Miguel JF: Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2014, 32: 8510-Google Scholar
- Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL: Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014, 343: 301-305.PubMed CentralPubMedGoogle Scholar
- Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG: The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014, 343: 305-309.PubMed CentralPubMedGoogle Scholar
- Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, Schafer PH, Chopra R: Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014, 164: 811-821.PubMed CentralPubMedGoogle Scholar
- Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Cullis CA: An inhibitor of NEDD8-activating enzyme as a novel approach to treat cancer. Nature. 2009, 458: 732-736.PubMedGoogle Scholar
- Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH, Weissman AM: Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007, 67: 9472-9481.PubMedGoogle Scholar
- Chen JJ, Tsu CA, Gavin JM, Milhollen MA, Bruzzese FJ, Mallender WD, Sintchak MD, Bump NJ, Yang X, Ma J, Loke HK, Xu Q, Li P, Bence NF, Brownell JE, Dick LR: Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. J Biol Chem. 2011, 286: 40867-40877.PubMed CentralPubMedGoogle Scholar
- ClinicalTrials.gov, search term, "MLN7243". In , [http://clinicaltrials.gov/ct2/show/NCT02045095?term=mln7243&rank=1]
- Volkmann K, Lucas JL, Vuga D, Wang X, Brumm D, Stiles C, Kriebel D, Der-Sarkissian A, Krishnan K, Schweitzer C, Liu Z, Malyankar UM, Chiovitti D, Canny M, Durocher D, Sicheri F, Patterson JB: Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem. 2011, 286: 12743-12755.PubMed CentralPubMedGoogle Scholar
- Cross BC, Bond PJ, Sadowski PG, Jha BK, Zak J, Goodman JM, Silverman RH, Neubert TA, Baxendale IR, Ron D, Harding HP: The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A. 2012, 109: E869-E878.PubMed CentralPubMedGoogle Scholar
- Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, Solow-Cordero DE, Bouley DM, Offner F, Niwa M, Koong AC: Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011, 117: 1311-1314.PubMed CentralPubMedGoogle Scholar
- Wang H, Blais J, Ron D, Cardozo T: Structural determinants of PERK inhibitor potency and selectivity. Chem Biol Drug Des. 2010, 76: 480-495.PubMedGoogle Scholar
- Harding HP, Zyryanova AF, Ron D: Uncoupling proteostasis and development in vitro with a small molecule inhibitor of the pancreatic endoplasmic reticulum kinase, PERK. J Biol Chem. 2012, 287: 44338-44344.PubMed CentralPubMedGoogle Scholar
- Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, Choudhry AE, Alsaid H, Jucker BM, Axten JM, Kumar R: Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013, 73: 1993-2002.PubMedGoogle Scholar
- Ye Y, Meyer HH, Rapoport TA: The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature. 2001, 414: 652-656.PubMedGoogle Scholar
- Dai RM, Chen E, Longo DL, Gorbea CM, Li CC: Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem. 1998, 273: 3562-3573.PubMedGoogle Scholar
- Li JM, Wu H, Zhang W, Blackburn MR, Jin J: The p97-UFD1L-NPL4 protein complex mediates cytokine-induced IkappaBalpha proteolysis. Mol Cell Biol. 2014, 34: 335-347.PubMed CentralPubMedGoogle Scholar
- Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Iizuka N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Aozasa K, Monden M: Valosin-containing protein (p97) and Ki-67 expression is a useful marker in detecting malignant behavior of pancreatic endocrine neoplasms. Oncology. 2004, 66: 468-475.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M, Yamamoto S, Iuchi K, Aozasa K: Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol. 2004, 11: 697-704.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K: Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2004, 11: 165-172.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Nakamori S, Sakon M, Monden M, Aozasa K: Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol. 2003, 21: 2537-2544.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M, Aozasa K: Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol. 2003, 21: 447-452.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Uruno T, Hoshida Y, Qiu Y, Iizuka N, Nakamichi I, Miyauchi A, Aozasa K: Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res. 2004, 10: 5558-5565.PubMedGoogle Scholar
- Yamamoto S, Tomita Y, Uruno T, Hoshida Y, Qiu Y, Iizuka N, Nakamichi I, Miyauchi A, Aozasa K: Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. Ann Surg Oncol. 2005, 12: 925-934.PubMedGoogle Scholar
- Fessart D, Marza E, Taouji S, Delom F, Chevet E: P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013, 337: 26-34.PubMedGoogle Scholar
- Verma R, McDonald H, Yates JR, Deshaies RJ: Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields active S phase cyclin-Cdk. Mol Cell. 2001, 8: 439-448.PubMedGoogle Scholar
- Franz A, Ackermann L, Hoppe T: Create and preserve: proteostasis in development and aging is governed by Cdc48/p97/VCP. Biochim Biophys Acta. 1843, 2014: 205-215.Google Scholar
- Meyer H, Bug M, Bremer S: Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012, 14: 117-123.PubMedGoogle Scholar
- Carvalho P, Goder V, Rapoport TA: Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell. 2006, 126: 361-373.PubMedGoogle Scholar
- Verma R, Oania R, Fang R, Smith GT, Deshaies RJ: Cdc48/p97 mediates UV-dependent turnover of RNA Pol II. Mol Cell. 2011, 41: 82-92.PubMed CentralPubMedGoogle Scholar
- Beskow A, Grimberg KB, Bott LC, Salomons FA, Dantuma NP, Young P: A conserved unfoldase activity for the p97 AAA-ATPase in proteasomal degradation. J Mol Biol. 2009, 394: 732-746.PubMedGoogle Scholar
- Verma R, Oania RS, Kolawa NJ, Deshaies RJ: Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. eLife. 2013, 2: e00308-PubMedGoogle Scholar
- Brandman O, Stewart-Ornstein J, Wong D, Larson A, Williams CC, Li GW, Zhou S, King D, Shen PS, Weibezahn J, Dunn JG, Rouskin S, Inada T, Frost A, Weissman JS: A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress. Cell. 2012, 151: 1042-1054.PubMed CentralPubMedGoogle Scholar
- Defenouillère Q, Yao Y, Mouaikel J, Namane A, Galopier A, Decourty L, Doyen A, Malabat C, Saveanu C, Jacquier A, Fromont-Racine M: Cdc48-associated complex bound to 60S particles is required for the clearance of aberrant translation products. Proc Natl Acad Sci U S A. 2013, 110: 5046-5051.PubMed CentralPubMedGoogle Scholar
- Buchan JR, Kolaitis RM, Taylor JP, Parker R: Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013, 153: 1461-1474.PubMed CentralPubMedGoogle Scholar
- Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, Weihl CC: Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol. 2009, 187: 875-888.PubMed CentralPubMedGoogle Scholar
- Ju JS, Miller SE, Hanson PI, Weihl CC: Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem. 2008, 283: 30289-30299.PubMed CentralPubMedGoogle Scholar
- Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, Yao TP, Dantuma NP, Taylor JP: VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy. 2010, 6: 217-227.PubMed CentralPubMedGoogle Scholar
- Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007, 447: 859-863.PubMedGoogle Scholar
- Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, Polucci P, Ballinari D, Perrera C, Leone A, Cervi G, Casale E, Xiao Y, Wong C, Anderson DJ, Galvani A, Donati D, O'Brien T, Jackson PK, Isacchi A: Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013, 9: 548-556.PubMedGoogle Scholar
- Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ: A reversible inhibitor of the AAA ATPase p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A. 2011, 108: 4834-4839.PubMed CentralPubMedGoogle Scholar
- Acharya P, Liao M, Engel JC, Correia MA: Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome p450 3A extraction into the cytosol. J Biol Chem. 2011, 286: 3815-3828.PubMed CentralPubMedGoogle Scholar
- Piccirillo R, Goldberg AL: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. 2012, 31: 3334-3350.PubMed CentralPubMedGoogle Scholar
- Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ: Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. Chem Med Chem. 2013, 8: 297-312.PubMed CentralPubMedGoogle Scholar
- Wang Q, Li L, Ye Y: Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem. 2008, 283: 7445-7454.PubMed CentralPubMedGoogle Scholar
- Bursavich MG, Parker DP, Willardsen JA, Gao ZH, Davis T, Ostanin K, Robinson R, Peterson A, Cimbora DM, Zhu JF, Richards B: 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97). Bioorg Med Chem Lett. 2010, 20: 1677-1679.PubMedGoogle Scholar
- Brown SJ, Chou TF, Deshaies R, Roberts E, Guerrero M, Minond D, Mercer BA, Hodder P, Rosen HR: Probe report for P97/cdc48 inhibitors. Probe Reports from the NIH Molecular Libraries Program. 2010, [http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/books/NBK47346/], [http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/books/NBK47346/]Google Scholar
- Sasazawa Y, Kanagaki S, Tashiro E, Nogawa T, Muroi M, Kondoh Y, Osada H, Imoto M: Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem Biol. 2012, 7: 892-900.PubMedGoogle Scholar
- Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, Castain C, Le Bail B, Simpson JC, Rosenbaum J, Balabaud C, Bioulac-Sage P, Blanc JF, Chevet E: Sorafenib-mediated targeting of the AAA(+) ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther. 2012, 11: 2610-2620.PubMedGoogle Scholar
- Ikeda HO, Sasaoka N, Koike M, Nakano N, Muraoka Y, Toda Y, Fuchigami T, Shudo T, Iwata A, Hori S, Yoshimura N, Kakizuka A: Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci Rep. 2014, 4: 5970-PubMed CentralPubMedGoogle Scholar
- Kang MJ, Wu T, Wijeratne EM, Lau EC, Mason DJ, Mesa C, Tillotson J, Zhang DD, Gunatilaka AA, La Clair JJ, Chapman E: Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action. Chembiochem. 2014, 15: 2125-2131.PubMed CentralPubMedGoogle Scholar
- Chou TF, Deshaies RJ: Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem. 2011, 286: 16546-16554.PubMed CentralPubMedGoogle Scholar
- Johnson ES, Ma PC, Ota IM, Varshavsky A: A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem. 1995, 270: 17442-17456.PubMedGoogle Scholar
- Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG: Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol. 2000, 18: 538-543.PubMedGoogle Scholar
- Kimbrel EA, Davis TN, Bradner JE, Kung AL: In vivo pharmacodynamic imaging of proteasome inhibition. Mol Imaging. 2009, 8: 140-147.PubMedGoogle Scholar
- Polucci P, Magnaghi P, Angiolini M, Asa D, Avanzi N, Badari A, Bertrand J, Casale E, Cauteruccio S, Cirla A, Cozzi L, Galvani A, Jackson PK, Liu Y, Magnuson S, Malgesini B, Nuvoloni S, Orrenius C, Sirtori FR, Riceputi L, Rizzi S, Trucchi B, O'Brien T, Isacchi A, Donati D, D'Alessio R: Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors: synthesis and structure-activity relationships. J Med Chem. 2013, 56: 437-450.PubMedGoogle Scholar
- Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ: Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010, 38: 17-28.PubMed CentralPubMedGoogle Scholar
- Steffen J, Seeger M, Koch A, Kruger E: Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 2010, 40: 147-158.PubMedGoogle Scholar
- Radhakrishnan SK, den Besten W, Deshaies RJ: p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife. 2014, 3: e01856-PubMed CentralPubMedGoogle Scholar
- Zhang Y, Ren Y, Li S, Hayes JD: Transcription factor Nrf1 is topologically repartitioned across membranes to enable target gene transactivation through its acidic glucose-responsive domains. PLoS One. 2014, 9: e93458-PubMed CentralPubMedGoogle Scholar
- Sha Z, Goldberg AL: Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol. 2014, 24: 1573-1583.PubMed CentralPubMedGoogle Scholar
- Wang W, Chan JY: Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain. Inhibition of nuclear translocation and transacting function. J Biol Chem. 2006, 281: 19676-19687.PubMedGoogle Scholar
- Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N: Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One. 2013, 8: e74415-PubMed CentralPubMedGoogle Scholar
- ClinicalTrials.gov, search terms "CB-5083" and "cleave". In , [clinicaltrials.gov/ct2/results?term=cb-5083+AND+cleave&Search=Search]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.